Micafungin for the prophylaxis and treatment of Candida infections

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 2, 2008, Pages 153-162

  Fritz, Joseph M ^a   Brielmaier, Benjamin D ^b   Dubberke, Erik R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Antifungal; Candidiasis; Echinocandin; Micafungin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; FK 486; FLUCONAZOLE; MICAFUNGIN; NIFEDIPINE; RAPAMYCIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; LIVER DISEASE; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHLEBITIS; PRURITUS; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT; REVIEW;

ANTIFUNGAL AGENTS; CANDIDIASIS; ECHINOCANDINS; HUMANS; LIPOPROTEINS;

EID: 45549108890     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.2.153     Document Type: Article

References (70)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41(9), 1232-1239 (2005).
3. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. 27(4), 781-788 (1998).
4. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit. Care Med. 34(3), 857-863 (2006).
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20(1), 133-163 (2007).
6. Pappas PG. Invasive candidiasis. Infect. Dis. Clin. North Am. 20(3), 485-506 (2006).
7. Barrett D. From natural products to clinically useful antifungals. Biochim. Biophys. Acta. 1587(2-3), 224-233 (2002).
8. Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents. Chemother. 44(1), 57-62 (2000).
9. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 46(3), 485-487 (2000).
10. Mycamine ® (micafungin sodium) product information: Astellas Pharma, OK, USA, June (2006).
11. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48, 471-497 (1994).
12. Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol. 3(3), 98-104 (1995).
13. Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays 28(8), 799-808 (2006).
14. Hakki M, Staab JF, Mary KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50(7), 2522-2524(2006).
15. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42(7), 938-944 (2006).
16. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49(2), 767-769 (2005).
17. Laverdière M, Lalonde RG, Basil JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57(4). 705-708 (2006).
18. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26(6). 877-880 (2006).
19. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucansynthase. Antimicrob. Agents Chemother. 51(5), 1876-1878 (2007).
20. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49(8), 3264-3273 (2005).
21. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin. Microbiol. 44(3), 760-763 (2006).
22. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida. a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44(10), 3533-3538(2006).
23. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47(10), 3149-3154 (2003).
24. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54(6),1051-1056 (2004).
25. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother. 53(2), 283-289 (2004).
26. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol. 44 (2), 324-326(2006).
27. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51(6), 2253-2256 (2007).
28. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51(5), 1616-1620(2007).
29. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43(11), 5425-5427 (2005).
30. Holm SE, Tornqvist IO, Cars O. Paradoxical effects of antibiotics. Scand. J. Infect. Dis. Suppl. 74, 113-117 (1990).
31. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50(4), 1293-7129 (2006).
32. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48(9), 3407-3411 (2004).
33. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51(3), 173-178 (2005).
34. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51(6), 2257-2259(2007).
35. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. 49(12), 5146-5148 (2005).
36. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 11(1), 30-36 (2003).
37. Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. Candida biofilm: a well-designed protected environment. Med Mycol. 43(3), 191-208 (2005).
38. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin. Microbiol. Rev. 17(2),255-267 (2004).
39. Nett J, Lincoln L, Marchillo K et al. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51(2), 510-520 (2007).
40. Nett J, Lincoln L, Marchillo K, Andes D. β3-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis. 195(11), 1705-1712 (2007).
41. Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob. Agents Chemother. 51(4), 1520-1523(2007).
42. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46(6), 1773-1180 (2002).
43. Seidler M, Salvenmoser S, Muller FM. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int. J. Antimicrob. Agents 28(6), 568-573 (2006).
44. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46(12), 3846-3853 (2002).
45. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chermother. 51(3), 968-974 (2007).
46. Ikeda F, Wakai Y, Matsumoto S et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44(3), 614-618 (2000).
47. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob.Agents Chemother. 46(6), 1857-1869 (2002).
48. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother. 49 (12), 4895-4902 (2005).
49. Hebert MF, Smith HE, Marbury TC et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45 (10), 1145-11452 (2005).
50. Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prohylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49(4), 1331-1336 (2005).
51. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemotber. 49(8), 3317-3324 (2005).
52. Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25(12), 1110-1115 (2006).
53. Darouiche RO. Echinocandins: ask not what they can do for esophageal candidiasis - ask what studies of esophageal candidiasis can do for them. Clin. Infect. Dis. 39(6), 850-852 (2004).
54. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol. Ther. 200), 475-481 (2004).
55. de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39(6), 842-849 (2004).
56. de Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol. Ther. 21(7), 899-907 (2005).
57. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39 (10), 1407-1416 (2004).
58. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34(1), 7-14 (2002).
59. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24(10), 654-661 (2005).
60. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 369(9572), 1519-1527 (2007).
61. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl J. Med. 356(24), 2472-2482 (2007).
62. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
63. AmBisome® (amphotericin B liposome for injection) product information: Astellas Pharma, OK, USA, July (2005).
64. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45(7), 883-983 (2007).
65. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 10(4), 239-253 (1992).
66. Sirohi B, Powles RL, Chopra R et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 38(1), 47-51 (2006).
67. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 45(8), 954-960 (2005).
68. Hebert MF, Blough DK, Townsend RW et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 45(9), 1018-1024 (2005).
69. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38(2), 161-189 (2004).
70. Cornely O, Lasso M, Betts R et al. Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of less common forms of invasive candidiasis (IC). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17-20 September 2006.